Arrowhead Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Arrowhead Pharmaceuticals has a total shareholder equity of $339.0M and total debt of $336.0M, which brings its debt-to-equity ratio to 99.1%. Its total assets and total liabilities are $883.8M and $544.8M respectively.
Key information
99.1%
Debt to equity ratio
US$336.03m
Debt
| Interest coverage ratio | n/a |
| Cash | US$434.47m |
| Equity | US$338.97m |
| Total liabilities | US$544.79m |
| Total assets | US$883.76m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: A2RR34's short term assets ($450.1M) exceed its short term liabilities ($96.7M).
Long Term Liabilities: A2RR34's short term assets ($450.1M) exceed its long term liabilities ($448.1M).
Debt to Equity History and Analysis
Debt Level: A2RR34 has more cash than its total debt.
Reducing Debt: A2RR34's debt to equity ratio has increased from 0% to 99.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A2RR34 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: A2RR34 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 47% each year